Cardiol Therapeutics Inc Dossier - Source-backed chat

Cardiol Therapeutics Inc

CRDLNASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)0.80

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.56Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $189.6M

Enterprise Value $168.2M

Shares Outstanding 121.5M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Cardiol Therapeutics is a late-stage clinical biopharmaceutical company developing targeted anti-inflammatory and anti-fibrotic therapies for rare and prevalent heart diseases. The investment thesis is anchored on the rapid clinical progression of its lead asset, CardiolRx™ (an oral cannabidiol solution), which is currently in a pivotal Phase III trial (MAVERIC) for recurrent pericarditis. With patient enrollment surpassing 75% and a robust cash runway extending into Q4 2027, Cardiol is fully funded through key clinical readouts. Positive Phase II ARCHER data in acute myocarditis further validates the therapeutic platform's mechanism of action, positioning the company to address significant unmet medical needs in orphan cardiovascular indications.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.87

Mean target$7.34

High · most bullish analyst$8.97

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.50

The Phase III MAVERIC trial experiences enrollment delays extending into 2027, pushing back the top-line data readout. If the trial fails to meet its primary efficacy endpoints or shows safety concerns, the clinical development path for CardiolRx™ in recurrent pericarditis would be severely compromised. This would force the company to rely solely on its earlier-stage CRD-38 program, leading to a significant drop in share price and requiring highly dilutive equity financing to sustain operations as the cash runway depletes.

Base CaseCentral scenario

$8.50

The Phase III MAVERIC trial completes enrollment in late 2026, with top-line data expected in 2027. The data confirms the safety and efficacy profile observed in the Phase II MAvERIC-Pilot study, supporting a clear path toward an NDA submission. Cardiol maintains disciplined cost management, preserving its cash runway into late 2027. The company continues to advance CRD-38 toward IND filing, and the stock experiences steady upward re-rating as clinical milestones are achieved, supported by a strong consensus buy rating from Wall Street analysts.

Bull CaseUpside scenario

$9.00

The pivotal Phase III MAVERIC trial meets all primary and secondary endpoints with high statistical significance, demonstrating superior efficacy of CardiolRx™ in preventing recurrent pericarditis compared to placebo. This triggers a rapid FDA New Drug Application (NDA) submission and subsequent approval, allowing Cardiol to capture a substantial share of the US recurrent pericarditis market (estimated at 40,000 patients annually). Concurrently, CRD-38 successfully enters Phase I clinical trials for heart failure, attracting a major pharmaceutical partnership with upfront licensing fees that significantly boost the valuation.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Lead asset CardiolRx™ is in a pivotal Phase III trial (MAVERIC) for recurrent pericarditis, a rare disease with a significant unmet need for non-immunosuppressive oral therapies.
Strong balance sheet with $27.7 million CAD in cash and equivalents as of Q1 2026, providing a fully funded operational runway into Q4 2027.
Positive Phase II ARCHER data in acute myocarditis published in peer-reviewed journals, validating the anti-inflammatory and anti-fibrotic mechanism of action.
Orphan Drug Designation granted by the FDA for CardiolRx™ in pericarditis, providing regulatory exclusivity and development incentives.

Key Investment Risks

Clinical trial risk: The company's valuation is heavily dependent on the success of the Phase III MAVERIC trial; any failure to meet primary endpoints would severely impact the investment case.
Regulatory risk: Potential delays or additional requirements from the FDA during the NDA submission and review process.
Pre-commercial stage: The company has no commercial revenues and expects continued net losses, relying entirely on capital markets or partnerships for funding.
Market adoption: Risk of slow commercial uptake or intense competition from established therapies once approved.

Thesis Invalidation Triggers

Failure of the Phase III MAVERIC trial to meet its primary efficacy endpoint of preventing recurrent pericarditis.
Unexpected serious adverse safety signals emerging during the MAVERIC trial, leading to a clinical hold by the FDA.
Severe delays in patient recruitment for the MAVERIC trial that exhaust the cash runway before top-line data can be delivered.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.